Exemestane and RAD-140 Interaction

Avoid
Mechanism-based 53% confidence

Exemestane and RAD-140 have a potentially harmful interaction with 53% confidence. Both Exemestane and RAD-140 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and liver and heart, so monitoring these systems is recommended.

Compound Profiles

Exemestane

Steroidal Aromatase Inhibitor | Irreversible Estrogen Control

Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase as a substrate analogue and enters the enzyme's active site.

Half-life: ~24 hours Typical dose: 12.5mg EOD or 25mg E3D (estrogen management) pct, anabolic
androgen receptoraromatase androgenicaromatase inhibitorestrogenichepatotoxic
View full profile

RAD-140

Selective Androgen Receptor Modulator | Investigational SARM

RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands.

Half-life: ~60 hours Typical dose: 10-20 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskcrosses bbb
View full profile

Combined Organ Load

Gonads
elevated
Liver
elevated
Heart
moderate
Pituitary
low

Shared Safety Flags

2x 2 androgenic compounds (Exemestane, RAD-140). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 hepatotoxic compounds (Exemestane, RAD-140). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (Exemestane, RAD-140). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (Exemestane, RAD-140). Get lipid panel mid-cycle — consider adding lipid support.

Frequently Asked Questions

Can I take Exemestane with RAD-140?

Combining Exemestane with RAD-140 is not recommended. Both Exemestane and RAD-140 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Exemestane and RAD-140 safe together?

This combination carries significant risk. Both Exemestane and RAD-140 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Exemestane and RAD-140?

Both Exemestane and RAD-140 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 53% confidence and is inferred from pharmacological mechanism analysis.

How should I time Exemestane and RAD-140?

Exemestane has a half-life of ~24 hours and RAD-140 has a half-life of ~60 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Exemestane vs RAD-140

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.